N-(3,5-dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide | 644983-17-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3,5-dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide
• 英文别名: N-[(3,5-dibromophenyl)methyl]-2-[4-(4-fluorophenyl)piperidin-4-yl]-N-methylacetamide
• CAS: 644983-17-5
• 化学式: C₂₁H₂₃Br₂FN₂O
• 分子量: 498.233
• InChiKey: IEGOVDNNVDRMGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3,5-dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide 、 环丙甲醛 在 三乙酰氧基硼氢化钠 作用下， 以 乙腈 为溶剂， 反应 1.5h， 生成 2-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-N-[(3,5-dibromophenyl)methyl]-N-methylacetamide
  参考文献：
  名称：

  [EN] SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  公开号：

  WO2004005256A3
• 作为产物：
  描述：

  4-{[(3,5-dibromobenzyl)methylcarbamoyl]methyl}-4-(4-fluorophenyl)-piperidine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 N-(3,5-dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide
  参考文献：
  名称：

  [EN] SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  公开号：

  WO2004005256A3

文献信息

• Chemical compounds
  申请人：Alvaro Giuseppe

  公开号：US20060128752A1

  公开（公告）日：2006-06-15

  The present invention relates to cyclic amine derivatives of formula(l) wherein R represents halogen, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R 1 represents hydrogen, halogen, C 3-7 cycloalkyl, hydroxy, nitro, cyano or C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 represents hydrogen or C 1-4 alkyl; R 3 and R 4 independently represent hydrogen, cyano, C 1-4 alkyl or R 3 together with R 4 represents C 3-7 cycloalkyl; R 5 represents trifluoromethyl, S(O) t C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, halogen or cyano; R 6 represents hydrogen or (CH 2 )rR 7 ; R 7 represents hydrogen, C 3 7 cycloalkyl, NH(C 1-4 alkylOC 1-4 alkoxy), NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , OC(O)NR 9 R 8 , NR 8 C(O)R 9 or C(O)NR 9 R 8 ; R 9 and R 8 independently represent hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m represents zero or an integer from 1 to 4; n represents 1 or 2; p is zero or an integer from 1 to 3; q is an integer from 1 to 3; r is an integer from 1 to 4; t is 0, 1 or 2; provided that when m is 0, p is 2, q , r and n represent 1, R 1 , R 2 ,R 3 , R 4 , R 5 and R 7 are hydrogen and R is chlorine, R 5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  本发明涉及式（I）的环状胺衍生物，其中R代表卤素、C1-4烷基、氰基、C1-4烷氧基、三氟甲基或三氟甲氧基；R1代表氢、卤素、C3-7环烷基、羟基、硝基、氰基或C1-4烷基，可选地被卤素、氰基或C1-4烷氧基取代；R2代表氢或C1-4烷基；R3和R4独立地代表氢、氰基、C1-4烷基或R3和R4一起代表C3-7环烷基；R5代表三氟甲基、S（O）tC1-4烷基、C1-4烷基、C1-4烷氧基、三氟甲氧基、卤素或氰基；R6代表氢或（CH2）rR7；R7代表氢、C37环烷基、NH（C1-4烷基OC1-4烷氧基）、NH（C1-4烷基）、N（C1-4烷基）2、OC（O）NR9R8、NR8C（O）R9或C（O）NR9R8；R9和R8独立地代表氢、C1-4烷基或C3-7环烷基；m代表零或1至4的整数；n代表1或2；p为零或1至3的整数；q为1至3的整数；r为1至4的整数；t为0、1或2；但当m为0，p为2，q、r和n均为1，R1、R2、R3、R4、R5和R7均为氢，R为氯时，R5不为碘；以及其药学上可接受的盐和溶剂化合物；其制备方法和在治疗由粘附素介导和/或选择性抑制血清素再摄取转运蛋白介导的疾病中的应用。
• SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1558577A2

  公开（公告）日：2005-08-03
• NK-1 RECEPTOR ANTAGONISTS FOR TREATING CORNEAL NEOVASCULARISATION
  申请人：IRBM - Science Park S.p.A.

  公开号：EP2729147B1

  公开（公告）日：2017-09-06
• Novel Method
  申请人：Ferrari Giulio

  公开号：US20140128395A1

  公开（公告）日：2014-05-08

  There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.
• TREATMENT OF CORNEAL NEOVASCULARIZATION
  申请人：IRBM SCIENCE PARK S.p.A.

  公开号：US20180021327A1

  公开（公告）日：2018-01-25

  There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.